LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.25 -0.1

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.24

Massimo

31.27

Metriche Chiave
By Trading Economics
Entrata	11M 64M
Vendite	-3.2M 149M
P/E Media del settore	18.052 49.701
EPS	0.79
Margine di Profitto	42.663
Dipendenti	182
EBITDA	2M 83M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+5.89% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	281M 3.8B
Apertura precedente	31.35
Chiusura precedente	31.25

Notizie sul Sentiment di mercato

By Acuity

100%

326 / 345 Classifica in Healthcare

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 mag 2026, 23:46 UTC

Discorsi di Mercato

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 mag 2026, 23:45 UTC

Discorsi di Mercato

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 mag 2026, 23:42 UTC

Discorsi di Mercato

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 mag 2026, 23:34 UTC

Discorsi di Mercato

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 mag 2026, 23:11 UTC

Discorsi di Mercato

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 mag 2026, 22:26 UTC

Acquisizioni, Fusioni, Takeovers

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 mag 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 mag 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 mag 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 mag 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 mag 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 mag 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 mag 2026, 22:11 UTC

Discorsi di Mercato

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 mag 2026, 22:04 UTC

Discorsi di Mercato

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 mag 2026, 08:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

23 mag 2026, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

22 mag 2026, 21:10 UTC

Utili

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2026, 19:47 UTC

Utili

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mag 2026, 19:17 UTC

Discorsi di Mercato

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mag 2026, 18:38 UTC

Discorsi di Mercato

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mag 2026, 18:35 UTC

Acquisizioni, Fusioni, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mag 2026, 18:09 UTC

Discorsi di Mercato

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mag 2026, 17:58 UTC

Discorsi di Mercato

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

5.89% in crescita

Previsioni per 12 mesi

Media 33.1 USD 5.89%

Alto 35 USD

Basso 31.5 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

326 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.